Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Endocrinology
Clinical Trials: Diabetes Mellitus, Type 1
A listing of clinical trials currently looking for volunteers to enroll in Diabetes Mellitus, Type 1 studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Huntsville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Arizona
Tuscon : University of Arizona
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Sierra Vista : Cochise Clinical Research
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Tucson : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Arkansas
Jonesboro : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Little Rock : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Little Rock : Arkansas Diabetes Clinic and Research Center
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Sherwood : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
California
Anaheim : Anaheim Clinical Trials (ACT)
Patients with Type I Diabetes needed for a clinical research trial.
Duarte : City of Hope Updated
Detection of Human Beta Cell Death in T1DM Methylation-Specific PCR
Duarte : City of Hope Updated
Long-Term Follow-Up of Islet Transplant Recipients
Duarte : City of Hope Updated
TrialNet TN-01: Trialnet Natural History Study of the Development of Type I Diabetes
Escondido : AMCR Institute, Inc.
Basal Insulin Diabetes Mellitus type 1
Escondido : AMCR Institute, Inc.
Do you want to try a new glucose meter?
Los Angeles : Children’s Hospital of Los Angeles
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
Sacramento : Sutter Institute for Medical Research (SIMR)
Diabetes Type 1 - Genetics
San Diego : UCSD Rady Children’s Hospital
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
View More »
Chula Vista : Profil Institute for Clinical Research
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Chula Vista : Profil Institute For Clinical Research, Inc.
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Chula Vista : Profil Institute for clinical Research
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in Type1 Diabetes
Chula Vista : Profil Institute for Clinical Research
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
Chula Vista : Profil Institute for Clinical Research
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Duarte : Novo Nordisk Clinical Trial Call Center
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Escondido : AMCR Institue
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Escondido : AMCR Institute, Inc
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Fresno : Research Center of Fresno
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Huntington Beach : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
La Mesa : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Lancaster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Long Beach : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Long Beach : Health Care Partners Medical Group
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Long Beach, : Long Beach Center for Clinical Research
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Los Gatos : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Los Gatos :
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Modesto : Sutter Gold Medical Foundation
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Orange : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Salinas : Diabetes Care Center
A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections
San Diego : Va San Diego Healthcare System
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
San Diego : San Diego Clinical Trials
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
San Francisco : University of California, San Francisco
Reversing Type 1 Diabetes After it is Established
San Mateo : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Santa Barbara : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Stanford : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Stanford : Stanford University and Stanford Hospital & Clinics
Medtronic Treat to Range (TTR) Closed-Loop Control
Torrance : La Biomed Research Inst. At Harbor Ucla Med Ctr.
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Tustin : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Tustin, : University Clinical Investigators, Inc. dba Diabetes Research Center
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Ventura : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Walnut Creek : Diablo Clinical Research
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Colorado
Aurora : University of Colorado, Barbara Davis Center for Childhood Diabetes
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Aurora : University of Colorado, Barbara Davis Center for Childhood Diabetes
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
Longmont : Longmont Medical Research Network
Research Study for Type 1 Diabetes
View More »
Aurora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Aurora : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Aurora : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Aurora : University of Colorado Hospital - Anschutz Outpatient Pavilion
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Aurora : Barbara Davis Center
Pramlintide in Adolescents With Type 1 Diabetes
Aurora : Barbara Davis Center for Childhood Diabetes
Reversing Type 1 Diabetes After it is Established
Denver : Creekside Endocrine Associates, Inc.
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Connecticut
New Haven : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Delaware
Wilmington : Alfred I duPont Hospital
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Florida
Aventura : South Florida Medical Research
A Phase 2B Repeat Dosing Clinical Trial of an Investigational Medication in Patients with Moderately Severe Diabetic Neuropathy
Miami : University of Miami School of Medicine
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Aventura : Innovative Medical Research of South Florida Inc.
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Bradenton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
DeLand :
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Gainesville : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Gainesville : University of Florida
Reversing Type 1 Diabetes After it is Established
Hialeah : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Hollywood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Hollywood : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Hollywood : The Center for Diabetes and Endocrine Care
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Inverness : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Jacksonville : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Jacksonville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Jacksonville : Nemours Children's Clinic
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Kissimmee, : FPA Clinical Research
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Melbourne : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Miami : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Miami : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Miami : Baptist Diabetes Associates, PA
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Miami : University of Miami, Miller School of Medicine
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
New Port Richey : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
New Smyrna Beach : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Orlando : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Orlando : Compass Research Phase 1, Llc
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Orlando : Orlando Diabetes & Endocrine Specialists, P.A.
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Orlando : Nemours Children's Clinic
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Ormond Beach : Ormond Medical Arts Pharmaceutical Research Center
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Palm Harbor : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Pensacola : Nemours Children's Clinic
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Port Orange : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Port Orange : Progressive Medical Research
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Tallahassee : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Tallahassee : Tallahassee Endocrine Associates
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Tampa : Diabetes and Hormonal Disease Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
West Palm Beach : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
West Palm Beach : Metabolic Research Institute
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Georgia
Atlanta : Pinnacle Trials, Inc.
Do you have both Diabetes & Asthma?
Atlanta : Children’s Healthcare of Atlanta at Egleston
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Atlanta : Atlanta Diabetes Associates
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Atlanta : Emory's Children's Center
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Atlanta : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Atlanta : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Atlanta : Atlanta Diabetes Associates
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Atlanta : Atlanta Diabetes Associates
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Dunwoody : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Lawrenceville : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Roswell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Roswell : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Roswell : Endocrine Research Solutions
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Hawaii
Idaho
Illinois
Chicago : Novo Nordisk Clinical Trial Call Center
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Chicago : Cedar-Crosse Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Oak Lawn : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Indiana
Indianapolis : Riley Hospital for Children, Indiana University
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Anderson : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Vincennes : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Iowa
Iowa City : University of Iowa
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Iowa City : University of Iowa Health Care
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Des Moines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Des Moines : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kansas
Kansas City : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Overland Park : Vince And Associates Clinical Research
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Topeka : Cotton-O'Neil Clinical Research Center, Diabetes & Endocrinology
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Diabetes: Diabetes Research Study Needs Volunteers
Lexington : University of Kentucky Chandler Medical Center
Diabetes: Have you recently been diagnosed with type 1 diabetes?
View More »
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Lexington : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Lexington : Central Kentucky Research Associates, Inc.
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Lexington : Kentucky Diabetes Endocrinology Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Louisville : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Louisiana
Maryland
Massachusetts
Boston : Joslin Diabetes Center
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Boston : Massachusetts General Hospital
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Boston : Massachusetts General Hospital
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
Worcester : UMASS Memorial Medical Center
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
View More »
Boston : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Boston : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Boston : Massachusettes General Hospital/ Diabetes Research Center
Comparison of Lantus and NPH Insulin in the Dawn Phenomenon
Boston : Novo Nordisk Clinical Trial Call Center
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Boston : Joslin Diabetes Center
Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy
Worcester : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Michigan
Kalamazoo : Jasper Clinic, Inc.
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Minnesota
Missouri
Kansas City : Children’s Mercy Hospital
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Kansas City : The Children’s Mercy Hospital
T1DAL: Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Chesterfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Jefferson City : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kansas City : Kansas City University Of Medicine And Biosciences
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Mexico : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
St Peters : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St. Louis : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St. Louis : Washington University
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Montana
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Billings : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Billings : Billings Clinic Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Nebraska
Omaha : Creighton University
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Omaha : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Nevada
New Hampshire
New Jersey
Hackensack : Advanced Biomedical Research, Inc. (ABR)
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Paramus : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
New Mexico
Albuquerque : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Santa Fe : Soutwest Clinical Research Center, LLC
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Exenatide (Byetta) vs Pramlintide (Symlin) Role in Post-Prandial Hyperglycemia
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
New Onset Type 1 Diabetes: Role of Exenatide
Bronx : Biomedical Research Alliance of New York
Type 1 Diabetes- two different insulin treatments.
New York : Naomi Berrie Diabetes Center
Proleukin and Rapamune in Type 1 Diabetes
New York : Naomi Berrie Diabetes Center at Columbia University Medical Center
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
New York : Columbia University
The ACCESS Trial for lupus with kidney disease (lupus nephritis)
Rochester : University of Rochester Medical Center, Strong Children’s Research Center
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Buffalo : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
New Hyde Park : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
New Hyde Park : North Shore Diabetes and Endocrine Associates
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
New York : Research Site
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
New York : MedHex Health
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Syracuse : Joslin Diabetes Center
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
North Carolina
Durham : University of North Carolina, Diabetes Care Center
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Asheville : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Ashville : Mountain Diabetes and Endocrine Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Durham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Durham : University of North Carolina Diabetes Care Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Fayetteville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Greenville : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Morehead City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Morehead City : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Raleigh : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Salisbury : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Winston-Salem : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Ohio
Cincinnati : Community Research
Diabetic struggling with your weight?
Columbus : Nationwide Children’s Hospital
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
View More »
Akron : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Athens : Ohio University College of Osteopathic Medicine
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Cincinnati : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Cincinnati : The Lindner Research Center, The Christ Hospital
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Cleveland : Cleveland Clinic
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Mentor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Oklahoma
Oklahoma City : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Oregon
Pennsylvania
Philadelphia : Children’s Hospital of Philadelphia
RETAIN (Part I): A Research Trial of Aralast in New Onset Type 1 Diabetes
Philadelphia : Children’s Hospital of Philadelphia
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Hershey : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Philadelphia : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Philadelphia : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Philadelphia : Nemours Children's Clinic-Jefferson
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Pittsburgh : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
South Carolina
South Dakota
Rapid City : Regional Medical Clinic-Endocrinology
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Tennessee
Texas
Dallas : University of Texas Southwestern
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Arlington : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Austin : Texas Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Dallas : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Dallas : Dallas Diabetes & Endocrine Center
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Dallas : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Dallas : Diabetech
Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes
Dallas : UT Southwestern Medical Center
Effects of Metreleptin in Type 1 Diabetes Mellitus
Dallas : Research Institute of Dallas
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
El Paso : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
El Paso : Sergio Rovnver, MD
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Houston : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Houston : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Round Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
San Antonio : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
San Antonio : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
San Antonio : Cetero Research
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
San Antonio : SAM Clinical Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Utah
Virginia
Norfolk : Eastern Virginia Medical School Department of Internal Medicine
The primary goal of the study is to investigate the safety and tolerability of the investigational drug, lisofylline, when administered under the skin or in the vein, in people with type 1 diabetes. A second aim is to determine how much drug is available in the blood after injection under the skin, compared to injection in the vein.
View More »
Charlottesville : University of Virginia
A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)
Norfolk : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Richmond : Novo Nordisk Clinical Trial Call Center
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Richmond : Dominion Medical Associates, Inc.
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Washington
Renton : Rainier Clinical Research Center, Inc.
Do you have Type 1 Diabetes? Rainier Clinical Research Center is seeking participants who have been diagnosed with type 1 diabetes and are interested in participating in a study of a new investigational insulin
Renton : Rainier Clinical Research Center, Inc.
Type 1 Diabetes and have Diabetic Peripheral Neuropathy
Seattle : Benaroya Research Institute at Virginia Mason Research Center
T1DAL: A Clinical Research Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept
View More »
Federal Way : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Federal Way : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Renton : Rainier Clinical Research Center
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Renton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Renton : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Renton : Rainier Clinical Research Center
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Seattle : Seattle Children's Hospital
The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Spokane : Northside Internal Medicine Associates, PS
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Tacoma : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Tacoma : Multicare Specialties Research
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Wisconsin
Madison : University of Wisconsin
Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
Madison : Novo Nordisk Clinical Trial Call Center
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Algeria
Algeries : Investigational Site Number 01201 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Algiers : Investigational Site Number 01202 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Algiers : Investigational Site Number 01204 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Algiers : Investigational Site Number 01203 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Argentina
Caba : Investigational Site Number 03202 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Caba : Investigational Site Number 03201 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Morón : Investigational Site Number 03205 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Australia
Box Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Keswick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Meadowbrook : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Merewether : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Parkville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Perth : University of Western Australia
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial
Austria
Belarus
Minsk : Belarusian Medical Academy of Postgraduate Education
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Minsk : Endocrinological Unit 1st City Clinical Hospital
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Minsk : Health Institution City Endocrinological Dispensary
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Minsk : Republican center of Medical Rehabilitation and Balneotherapy
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Mogilov : Health Institution Mogilev Diagnostic Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Belgium
Brugge : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Bruxelles : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Gent : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
View More »
Huy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Sint-Niklaas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Brazil
Bulgaria
Varna :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Canada
Calgary : LMC Endocrinology Centres
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Edmonton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Edmonton :
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Etobicoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Halifax : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Laval : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Oakville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Oakville : LMC Endocrinology Centres
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Red Deer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Toronto : Hospital for Sick Children
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial
Toronto : LMC Endocrinoly Centres
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Toronto : 1245.46.10001 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BI 10773 in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
China
Beijing : Investigational Site Number 156001 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Beijing : Investigational Site Number 156007 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Changsha : Investigational Site Number 156009 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Guangzhou : Investigational Site Number 156008 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Hangzhou : Investigational Site Number 156004 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
View More »
Shanghai : Investigational Site Number 156016 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Taiyuan : Investigational Site Number 156019 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Wuhan : Investigational Site Number 156002 Updated
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Colombia
Bogotá : Investigational Site Number 17004 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Bogotá : Investigational Site Number 17007 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Bogotá : Investigational Site Number 17005 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Medellin : Investigational Site Number 17006 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Czech Republic
Prague : Fakultni nemocnice Kralovske Vinohrady - II. internal department
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Prague : IKEM/Diabetes Centre/Videnska
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Denmark
Finland
Espoo :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Oulu : Tutkimusyksikko
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Porvoo : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Tampere : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
France
Bar Le Duc : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Caen : CHU Côte de Nacre
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Corbeil-Essonnes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Dommartin les Touls : Hôpital Jeanne D'Arc
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
La Rochelle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Le Creuzot : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Lyon : Hôpital Universitaire Debrousse
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Marseille : Hôpital Sainte Marguerite
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Montpellier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Montpellier : CH La Peyronie
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Nice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Reims : American Memorial Hospital
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Rouen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Saint Mande : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Strasbourg :
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Toulouse :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Toulouse : UH Toulouse
Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy
Toulouse : CHU Rangueil
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Venissieux : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Germany
Aschaffenburg :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Augsburg :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Bad Mergentheim : Diabetes Zentrum Mergentheim
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
Bad Mergentheim : Bad Mergentheim Updated
The InsuPad in Daily Life Study
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
View More »
Berlin :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Dresden :
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Duisburg :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Dusseldorf : DDZ Studienzentrum Deutsches Diabetes Zentrum
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Eisenach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Essen :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Falkensee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Furth Im Wald :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Giessen : Universitatsklinikum Giessen
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Hannover :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Hannover : Diabetes Centre for Children and Adolescents, Kinderkrankenhaus auf der Bult
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Hannover : Diabetes-Zentrum für Kinder und Jugendliche
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
Köln-weiden :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Leipzig :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Mainz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Mainz : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Mayen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Munchen : Institut für Diabetesforschung an der Klinik und Hochschulambulanz für Kinder- und Jugendmedizin
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
München :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Munster : Institut für Diabetesforschung Münster GmbH
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Münster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Münster :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Neuss :
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes
Neuwied : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Pohlheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Rostock :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Simmern :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Stuttgart : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Ulm : Institut für Diabetes - Technology Forschungs - und Entwicklungsgesellschaft mbH an der Universität Ulm
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
Unterhachingen :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Wurzen :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Greece
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Chalkida : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Hungary
Szeged : University of Szeged Faculty of Medicin
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Veszprem : Veszprem Megyei Csolnoky Ferenc Korhaz es Rendelointezet Diabetologia Centrum
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Zalaegerszeg : Zala Megyei Korhaz es Rendelointezet Diabetologia Centrum
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
India
Bangalore : Diacon Hospital,(Diabetes Care and Research Centre)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
Bangalore : Bangalore Diabetes Hospital
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
Karnal : Bharti Research Institute of Diabetes and Endocrinology
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
Ireland
Israel
Bear Sheva : Soroka hospital
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
Beer Sheva : Diabetes Clinic Soroka University
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Beer Sheva : Soroka University Medical Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Beer-Sheva : Soroka University Medical Center
Evaluation of the Performance and Use of Non-Invasive Glucose Monitoring Device
Haifa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Haifa : Rambam Medical Cent
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Haifa : Rambam Hospital
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
Holon : Wolfson Medical Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Jerusalem : Hadassah Medical Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Jerusalem : Health care unit- Jerusalem
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
Petaach-Tikva : Schneider Children's Medical center
MD Logic Pump Advisor- Adults Study
Petach Tikva : Schneider Medical Center
Performance Study of the SOLO 2.0 Insulin Pump
Petach-Tikva : Schneider Children's Medical center
MD Logic Pump Advisor -Pediatric Study
Petach-Tikva : Schnider children medical center
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
Petach-Tiqva : Institute for Endocrinology and Diabetes Schneider Children's MC
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Petah Tikva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Petah Tiqva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Tel Aviv : Sourasky Medical Center,
Performance Study of the SOLO 2.0 Insulin Pump
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Italy
Cagliari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Chieti :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Grosseto : P.O. di Grosseto - Stabilimento Misericordia
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Lecce : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Mariano Comense : Az. Osp. S. Anna - Presidio Ospedaliero Cantù - Mariano Comense
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
View More »
Milan : Istituto Scientifico San Raffaele
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Milan : Ospedale Niguarda Cà Granda
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Milan : Fondazione Centro San Raffaele del Monte Tabor
Reparixin in Pancreatic Islet Transplantation
Naples : II Università di Napoli Centro Regionale di Diabetologia Pediatrica "G. Stoppoloni"
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Padua : Università degli Studi di Padova Dipartimento di Medicina Clinica e Sperimentale
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Palermo : . Endocrinologia e Malattie Metaboliche, Dipartimento biomedico di medicina interna e specialistica, Ex Istituto di clinica medica, Università di Palerm
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Perugia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Pisa : Ospedale Cisanello
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Ravenna : U.O. di Diabetologia, Dip. di Malattie Digestive & Metaboliche
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Rome : University La Sapienza, Policlinico Umberto I
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Rome : Dept. of Endocrinology and Diabetes University Campus Bio-Medico
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Rome : Ospedale Sandro Pertini
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Turin : Azienda Ospedaliera-Universitaria S. Giovanni Battista
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Japan
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Tokyo :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Lithuania
Jonava : Private Clinic JSC 'Kristavita'
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Kaunas : Kaunas Medical University Hospital
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Vilnius : Vilnius Medical University Hospital, Santariskiu Clinic's
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Vilnius : Public Institution 'Seskines Outpatient Clinic'
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Macedonia, The Former Yugoslav Republic of
Skopje :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Mexico
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Guadalajara : Investigational Site Number 48402 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Guadalajara : Investigational Site Number 48401 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Guadalajara : Investigational Site Number 48404 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Guadalajara Jalisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
View More »
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Monterrey : Investigational Site Number 48403 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Netherlands
Amersfoort :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Dordrecht : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Gouda : Administrative office
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
Groningen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Heerlen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Leiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Zwijndrecht : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
New Zealand
Norway
Bergen : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Philippines
Makati City : Beverly Hills Medical Group
Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes
Quezon City : Veterens Memorial Medical Centre
Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes
Poland
Bialystok : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Bydgoszcz : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Gdansk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Katowice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Katowice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Kielce : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Krakow : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Lodz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Lodz : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Lodz : NZOZ OmniMed
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Lubin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Olsztyn : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Poznan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Szczecin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Szczecin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Warszawa : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Russian Federation
Arkhangelsk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Chelyabinsk : State Educational Institution for Additional Professional Education (SEIAPE) "Ural State Medical
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Kemerovo : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kemerovo : Kemerovo Regional Clinical Hospital
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Moscow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
View More »
Moscow :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Moscow : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Moscow : Endocrinological scientific center of Rosmedtechnology
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Moscow : City Clinical Hospital #81, Endocrinology Department
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Moscow : Clinic of New Medical Technology, LLC
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Moscow : SEIAPE Endocrinology and Diabetology
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Nizhni Novgorod : State Healthcare Institution (SHI) "Nizhegorodskaya
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Perm : State Healthcare Institution Perm Region Clinical Hospital
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Petrozavodsk : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Saint Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 1 Diabetes Mellitus
Samara : Limited Liability Company (LLC), Diabetes Center
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Smolensk : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St Petersburg : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St Petersburg : State Educational Institution of Higher Professional Education
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
St. Peterburg : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St. Petersburg : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St. Petersburg : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
St. Petersburg : St. Petersburg State Healthcare Institution
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Tomsk : Siberian State Medical University of Roszdrav
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Yaroslavl : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Saudi Arabia
Riyadh : Investigational Site Number 1 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Slovakia
Slovenia
South Africa
Benoni : Investigational Site Number 12468 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Bloemfontein : Investigational Site Number 12466 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Cape Town :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Durban : Investigational Site Number 12464 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Houghton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
View More »
Port Elizabeth : Investigational Site Number 12484 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Pretoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Pretoria : Investigational Site Number 12467 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Somerset West : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Spain
Alcala De Henares : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Alcira : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Las Palmas de Gran Canaria : Complejo Hospitalario Universitario Insular Materno-Infantil
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Lleida : Hospital Universitari Arnau de Vilanova
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
View More »
Málaga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Seville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Valencia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Sweden
Alingsås : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Helsingborg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Huddinge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Karlstad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Stockholm : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
View More »
Uppsala : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Switzerland
Basel :
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
Genève 14 :
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Zurich :
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
Tunisia
Sfax : Investigational Site Number 78801 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Tunis : Investigational Site Number 78803 Updated
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Ukraine
Dnipropetrovsk : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Donetsk : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kharkiv : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kyiv : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Kyiv : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
View More »
Odesa : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Odesa : Updated
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
United Kingdom
Birmingham :
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
Blackburn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Blackburn :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Bournemouth :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Bradford :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
View More »
Bristol : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Chester :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Cosham :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Coventry :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Derby :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Exeter :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Glasgow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Glasgow :
REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
Guildford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Headington :
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
High Wycombe : Wycombe Hospital
Comparing Long-acting Insulins During Exercise in Type 1 Diabetes
Inverness : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Ipswich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Leicester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Leicester :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Lindley, Huddersfield :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Middlesborough :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Northampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Northampton :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Nottingham :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Oxford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Portsmouth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Rotherham :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Scunthorpe :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Sheffield :
ACCU-CHEK Aviva Expert Study: Does Use of an Insulin Bolus Advisor Improve Glycemic Control in Patients Failing MDI/ICT?
Swansea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type I Diabetes Mellitus
Swansea : Clinical Research Unit
Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)
United States
Washington : George Washington University Medical Faculty Associates
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
